Vericel to Host Fourth-Quarter 2014 Earnings Call on March 23, 2015
CAMBRIDGE, Mass., March 12, 2015 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following conference call and webcast:
| What: | Vericel, Inc., Fourth Quarter 2014 Earnings Call |
| When: | Monday, March 23, 2015 at 4:30pm (EDT) |
| Where: | http://investors.vcel.com/events.cfm |
| How: |
-- The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events.cfm. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
|
-- To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth quarter 2014 investor conference call. If calling from outside the U.S., please use the international phone number (253) 237-1173. |
If you are unable to participate during the live call, the webcast will be available at http://investors.vcel.com/events.cfm until March 23, 2016. A replay of the call will also be available until 11:59 pm (EDT) on March 27, 2015 by calling (855) 859-2056, or from outside the U.S. at (404) 537-3406. The conference ID is 84844964.
About Vericel Corporation
Vericel Corporation (formerly Aastrom Biosciences, Inc.) is a leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. Vericel is also developing MACI™, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922